top of page
pexels-jopwell-2422293.jpg

ree

A Three-Part Webinar Series Aimed at Identifying and Prioritizing Intervention Research Topics Linked to Care Recipient Placement in Assisted Living Settings and the Challenges of Maintaining a Continued Caregiving Role


Webinar Series Overview
  •  Designed for researchers engaged with family caregivers of persons living with dementia

  • Discussion will focus on the challenges family caregivers have faced placing a care recipient

  • in an assisted living community

  • Learn from a panel of family caregivers of assisted living residents with dementia from across the country, as well as insights from several studies focused on this topic

Tuesday, September 16th

2:00p-3:30p Eastern Time

  • Design Principles presentation

  • Caregivers share challenges/problems

Tuesday, September 23rd

2:00p-3:30p Eastern Time

  • What caregivers wished they knew

Tuesday, September 30th

2:00p-3:30p Eastern Time

  • Presentation & insight from studies of caregiving in assisted living settings



Science-backed gerotherapeutics can target the biological mechanisms of aging in order to extend health and prevent and delay diseases and conditions common to our bodies as we grow older. Bolstered by discoveries at academic labs and emerging biotech companies, these innovations are poised to move from bench to bedside.


And from The New York Times to WIRED, the BBC to Netflix, National Geographic to JAMA and beyond, the promise of these age-targeting therapeutic interventions — such as Metformin, Rapamycin, and even GLP-1s — continues to generate media attention and tantalize consumers. At the same time, an explosion of “anti-aging” supplements and claims of biohacking “remedies” from questionable sources is muddying the waters.


Amid this buzz, how do we distinguish the hype from the hope and the science from the spin?

To provide a reality check on the readiness and intentions of gerotherapeutics, AFAR and the Academy for Health and Lifespan Research (AHLR) invite you to a free webinar on the current state of existing and emerging drug interventions to extend healthspan, our years of health as we grow older.


Renowned leaders from the academic, clinical, and private sectors will:

  • Clarify how both repurposing existing drugs and developing novel compounds can extend healthspan

  • Unpack the need for human trials, the importance of an FDA indication for aging, as well as the risks in off-label use and harm of radical life extension claims

  • Counter myths and misinformation with accurate expectations and language

  • Confront barriers that impact gerotherapeutics from safely entering the market

  • Explore how drug and lifestyle interventions work together to help us live healthier, longer at any age


The expert-backed conversation also will touch on hot topics such as the federal path to drug discovery, the momentum of the private biotech sector, the emerging use of GLP1s and SGL2s to extend healthspan, and what’s needed next to bring these promising therapeutics to consumers and clinicians soon.


Please join for an expert-led conversation on the promise of therapeutics to help us all live healthier, longer!


bottom of page